Player FM 앱으로 오프라인으로 전환하세요!
Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions
Manage episode 346581938 series 3256997
In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:
- Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
- Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
- Approval of ibrutinib/venetoclax combination therapy for patients with CLL
- Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
- How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor
Faculty:
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas
Nicole Lamanna, MD
Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
Link to the complete program, including downloadable slidesets and an on-demand webcast:
https://bit.ly/3EjvSKm
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
213 에피소드
Manage episode 346581938 series 3256997
In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:
- Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
- Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
- Approval of ibrutinib/venetoclax combination therapy for patients with CLL
- Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
- How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor
Faculty:
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas
Nicole Lamanna, MD
Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
Link to the complete program, including downloadable slidesets and an on-demand webcast:
https://bit.ly/3EjvSKm
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
213 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.